ClinicalTrials.gg

Program

upadacitinib

Also written as “Upadacitinib”, “ABT-494” and “Upadacitinib 15 MG [Rinvoq]”.

Its studies are mostly in Dermatitis, Atopic · Arthritis, Rheumatoid · Crohn Disease · Colitis, Ulcerative · Alopecia Areata, led by 3 companies.

Furthest: phase 4, since Aug 18, 202264 company-led studies, 24 open or runningNext primary completion: Nov 2026 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
AbbVie6121 open or runningphase 4since Aug 18, 2022Dec 3, 2012Nov 2026phase 3 · NCT06389136
CARE ARTHRITIS22 open or runningphase 4since Jun 6, 2024Jun 6, 2024May 2027phase 4 · NCT07018206
Modern Biosciences11 open or runningphase 1since Apr 8, 2024Apr 8, 2024none ahead

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

Before these, 47 studies since Feb 16, 2015.

  1. Apr 25, 20242 phase 3 studies in Dermatitis, AtopicAbbVie · NCT06389136, NCT06390722
  2. Jun 6, 2024CARE ARTHRITIS's first study: phase 4 study in Arthritis, PsoriaticNew to CARE ARTHRITISCARE ARTHRITIS · NCT06454188 · 100 planned · United States, Canada
  3. Jun 12, 2024Phase 3 study in Dermatitis, AtopicAbbVie · NCT06461897 · 699 enrolled · United States, Argentina, Australia and more
  4. Nov 21, 2024Phase 3 study in Dermatitis, AtopicAbbVie · NCT06701331 · 99 enrolled · Japan
  5. May 27, 2025Phase 4 study in Axial SpondyloarthritisCARE ARTHRITIS · NCT07018206 · 200 planned · United States
  6. Jun 10, 2025Phase 3 study in Alopecia AreataAbbVie · NCT07023302 · 125 enrolled · Japan
  7. Feb 17, 2026Phase 1 study in Healthy VolunteerAbbVie · NCT07425899 · 16 enrolled · United States
  8. Aug 11, 2026Phase 3 study in Alopecia AreataAbbVie · NCT07772492 · 300 planned · United States, Australia, Japan and more
  9. Sep 22, 2026Phase 1 study in Healthy VolunteersAbbVie · NCT07843693 · 60 planned · United States
  10. Oct 16, 2026Primary completion moved from 2027-06 to 2031-01Date moved laterphase 3 · +43 months · NCT06332534
  11. Oct 16, 2026Primary completion moved from 2026-08 to 2026-11Date moved laterphase 3 · +3 months · NCT06389136
  12. Oct 21, 20262 phase 3 studiesAbbVie · NCT07896434, NCT07933211
  13. Oct 23, 2026Phase 2 study in Arthritis, RheumatoidAbbVie · NCT07904754 · 250 planned
  14. Nov 13, 2026Primary completion moved from 2028-03 to 2028-08Date moved laterphase 3 · +5 months · NCT05889182

Ahead

  1. Nov 2026Primary completion: phase 3 study in Dermatitis, AtopicAbbVie · NCT06389136
  2. Dec 2026Primary completion: phase 1 study in Healthy VolunteersAbbVie · NCT07843693
  3. Jan 2027Primary completion: phase 3 study in Dermatitis, AtopicAbbVie · NCT06701331
  4. Mar 2027Primary completion: phase 3 study in Lupus Erythematosus, SystemicAbbVie · NCT05843643

TargetBeta

“Tyrosine-protein kinase TYK2 inhibitor; Tyrosine-protein kinase JAK3 inhibitor; Tyrosine-protein kinase JAK2 inhibitor; Tyrosine-protein kinase JAK1 inhibitor”ChEMBL 37, by rule

Other programs on the same 4 targets

ProgramCompanyFurthest phaseStudies
ruxolitinibruleIncytephase 495
tofacitinibrulePfizerphase 494
filgotinib maleateruleEisaiphase 42
filgotinibruleLakefront Biotherapeutics NVphase 346
delgocitinibruleLEO Pharmaphase 321

Studies

The newest 60 of 64 led by companies developing it. Each opens its study page. Every study on its drug page →

StudyPhaseStatusLed byPrimary completionSize
NCT07933211Scleroderma, Systemic3Not yet recruitingAbbVieJun 2035580
NCT07904754Arthritis, Rheumatoid2Not yet recruitingAbbVieJul 2029250
NCT07896434Non-Segmental Vitiligo3Not yet recruitingAbbVieAug 2032154
NCT07843693Healthy Volunteers · United States1RecruitingAbbVieDec 202660
NCT07772492Alopecia Areata · United States, Australia, Japan and more3RecruitingAbbVieMar 2032300
NCT07425899Healthy Volunteer · United States1CompletedAbbVieJun 5, 202616
NCT07023302Alopecia Areata · Japan3Active, not recruitingAbbVieFeb 2029125
NCT07018206Axial Spondyloarthritis · United States4Not yet recruitingCARE ARTHRITISMay 2027200
NCT06701331Dermatitis, Atopic · Japan3Active, not recruitingAbbVieJan 202799
NCT06461897Dermatitis, Atopic · United States, Argentina, Australia and more3Active, not recruitingAbbVieNov 2029699
NCT06454188Arthritis, Psoriatic · United States, Canada4RecruitingCARE ARTHRITISSep 2028100
NCT06390722Dermatitis, Atopic3WithdrawnAbbVieJan 5, 20260
NCT06389136Dermatitis, Atopic · United States, Canada, Colombia and more3Active, not recruitingAbbVieNov 2026184
NCT06379958Pharmacokinetics · United Kingdom1RecruitingModern BiosciencesSep 30, 202448
NCT06332534Crohn Disease · United States, Australia, Belgium and more3Active, not recruitingAbbVieJan 2031111
NCT06118411Vitiligo · United States, Argentina, Belgium and more3Active, not recruitingAbbVieMar 2028614
NCT06012240Alopecia Areata · United States, Argentina, Australia and more3RecruitingAbbVieApr 20301,500
NCT05889182Hidradenitis Suppurativa · United States, Argentina, Australia and more3Active, not recruitingAbbVieAug 20281,328
NCT05843643Lupus Erythematosus, Systemic · United States, Argentina, Australia and more3Active, not recruitingAbbVieMar 20271,014
NCT05814627Arthritis, Rheumatoid · United States, Argentina, Belgium and more3CompletedAbbVieJul 15, 2026487
NCT05782907Colitis, Ulcerative · United States, Australia, Belgium and more3Active, not recruitingAbbVieAug 2028122
NCT05609630Arthritis, Juvenile · United States, Argentina, Australia and more3RecruitingAbbVieJun 202990
NCT05601882Dermatitis, Atopic · United States, Australia, Belgium and more3CompletedAbbVieMar 19, 2024920
NCT05507580Dermatitis, Atopic · Australia, Belgium, Bulgaria and more4CompletedAbbVieJul 11, 2024461
NCT04927975Vitiligo · United States, Canada, France and more2CompletedAbbVieJan 13, 2023185
NCT04666675Dermatitis, Atopic3WithdrawnAbbVieMar 23, 20210
NCT04451772Lupus Erythematosus, Systemic · United States, Argentina, Australia and more2CompletedAbbVieJan 3, 2024185
NCT04430855Hidradenitis Suppurativa · United States, Canada, Japan and more2CompletedAbbVieApr 22, 202168
NCT04195698Dermatitis, Atopic · United States, Australia, Canada and more3CompletedAbbVieSep 11, 2023475
NCT04169373Spondylarthritis · United States, Argentina, Australia and more3CompletedAbbVieSep 2, 2021734
NCT04161898Takayasu Arteritis · Argentina, Brazil, China and more3Active, not recruitingAbbVieAug 202856
NCT03978520Lupus Erythematosus, Systemic · United States, Argentina, Australia and more2CompletedAbbVieJan 19, 2022341
NCT03823378Arthritis, Rheumatoid · Belgium, Canada, Czechia and more2TerminatedAbbVieSep 9, 202097
NCT03738397Dermatitis, Atopic · United States, Australia, Canada and more3CompletedAbbVieAug 27, 2020673
NCT03725202Giant Cell Arteritis · United States, Australia, Austria and more3CompletedAbbVieFeb 6, 2024429
NCT03725007Arthritis, Juvenile · United States, Canada, Germany and more1Active, not recruitingAbbVieDec 2028124
NCT03682705Arthritis, Rheumatoid · United States, Belgium, Canada and more2CompletedAbbVieMar 26, 2020242
NCT03661138Dermatitis, Atopic · Japan3CompletedAbbVieAug 19, 2022272
NCT03653026Colitis, Ulcerative · United States, Argentina, Australia and more3CompletedAbbVieJan 14, 2021522
NCT03646604Dermatitis, Atopic · United States, Norway, Puerto Rico1CompletedAbbVieAug 29, 202435
NCT03607422Dermatitis, Atopic · United States, Australia, Austria and more3CompletedAbbVieMar 11, 2021912
NCT03569293Dermatitis, Atopic · United States, Argentina, Australia and more3CompletedAbbVieJan 6, 2021912
NCT03568318Dermatitis, Atopic · United States, Australia, Austria and more3Active, not recruitingAbbVieFeb 16, 20211,533
NCT03345849Crohn Disease · United States, Argentina, Australia and more3CompletedAbbVieOct 15, 2021526
NCT03345836Crohn Disease · United States, Argentina, Australia and more3CompletedAbbVieAug 11, 2021624
NCT03345823Crohn Disease · United States, Argentina, Australia and more3Active, not recruitingAbbVieSep 2027747
NCT03178487Spondylitis, Ankylosing · United States, Australia, Belgium and more2CompletedAbbVieJan 21, 2019187
NCT03104400Arthritis, Psoriatic · United States, Argentina, Australia and more3CompletedAbbVieSep 26, 20191,705
NCT03104374Arthritis, Psoriatic · United States, Australia, Belgium and more3CompletedAbbVieJul 23, 2019642
NCT03006068Colitis, Ulcerative · United States, Argentina, Australia and more3Active, not recruitingAbbVieJul 2027950
NCT02955212Arthritis, Rheumatoid · Brazil, China, Korea, Republic of3CompletedAbbVieAug 14, 2019338
NCT02925117Dermatitis, Atopic · United States, Australia, Canada and more2CompletedAbbVieAug 10, 2017167
NCT02819635Colitis, Ulcerative · United States, Argentina, Australia and more3CompletedAbbVieDec 13, 20211,302
NCT02782663Crohn Disease · United States, Belgium, Canada and more2CompletedAbbVieJul 18, 2025107
NCT02720523Arthritis, Rheumatoid · Japan3CompletedAbbVieAug 3, 2017197
NCT02706951Arthritis, Rheumatoid · United States, Argentina, Australia and more3CompletedAbbVieOct 2, 2017648
NCT02706873Arthritis, Rheumatoid · United States, Argentina, Australia and more3CompletedAbbVieMar 15, 20181,002
NCT02706847Arthritis, Rheumatoid · United States, Australia, Austria and more3CompletedAbbVieApr 3, 2017499
NCT02675426Arthritis, Rheumatoid · United States, Argentina, Australia and more3CompletedAbbVieApr 21, 2017661
NCT02365649Crohn Disease2CompletedAbbVieNov 25, 2016220

How it is read

Names in the registry

  • “Upadacitinib”, 54 entries
  • “ABT-494”, 4 entries
  • “Upadacitinib 15 MG [Rinvoq]”, 2 entries
  • “Upadacitinib (ABT-494)”, 2 entries
  • “Upadacitinib 15mg Dose”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.